Explore Business Standard
The Madhya Pradesh government has formed a six-member committee to investigate how six children suffering from blood disorder thalassemia, including four treated at a hospital in Satna, contracted HIV infection, officials said. Tarun Rathi, Commissioner of the Public Health and Medical Education Department, issued an order on Tuesday announcing the formation of the investigation team and directed it to submit a report within seven days. The six children in the age group of 12 to 15 were found to be HIV positive after suspected contaminated blood transfusions at the district hospitals in Satna, Jabalpur and elsewhere. The parents of one of them were also found to be infected, officials said on Tuesday. Satna Collector Satish Kumar S told reporters that these infection cases came to light between January and May this year, and all the victims are currently undergoing treatment. "Children suffering from thalassemia were receiving regular blood transfusions. Six of them were found to b
Sex education should be provided to children from a younger age, and not Class IX onwards, the Supreme Court has said. A bench of Justices Sanjay Kumar and Alok Aradhe said sex education should be part of the curriculum in higher secondary schools so that young adolescents are made aware of the hormonal changes that come with puberty. "We are of the opinion that sex education should be provided to children from a younger age and not Class IX onwards. It is for the authorities concerned to apply their mind and take corrective measures, so that children are informed of the changes that happen after puberty, and the care and cautions to be taken in relation thereto," the bench said. The top court made the observations while granting bail to a 15-year-old boy accused of offences under sections 376 (rape) and 506 (criminal intimidation) of the IPC, and Section 6 (aggravated penetrative sexual assault) of the Protection of Children from Sexual Offences (POCSO) Act. The apex court earlier
Aurobindo Pharma on Tuesday said it will manufacture and supply the long-acting injectable HIV treatment cabotegravir across 133 countries. The Hyderabad-based drugmaker has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare, the company said in a statement. The agreement allows Aurobindo to manufacture and supply the long-acting injectable HIV treatment across 133 countries, including several low and middle-income markets, it added. This update now includes long-acting cabotegravir (CAB LA) for HIV treatment, in addition to its earlier use for prevention only. The treatment offers an alternative to daily pills, allowing patients to receive just one injection every one or two months. "We are privileged to be part of the sub-license expansion from MPP and ViiV to develop, manufacture, and distribute generic CAB LA in select markets for the treatment of HIV-1, in addition to t